
http://cancer.ucsd.edu/research-training/shared-resources/biorepository/Pages/default.aspx

UC San Diego MOORES CANCER CENTER An NCI-designated Comprehensive Cancer Center							
Cancer Treatment	Cancer Types	Patient Resources	Clinical Trials	About Us	Search Cancer Site		
Home / Research & Trai Research & Trai Registration Biorepository and Ti	ining Bior	ces / Biorepository and T		nnology	C Share		
Technology		Director					
Biostatistics	Scott Va	Scott VandenBerg, MD, PhD					
 DNA Sequencing Flow Cytometry 	Co-Di	Co-Director			Sharmeela Kaushal, PhD		
Histology and Immunohistochemis		Richard Schwab, MD Biorepository Manager					
 In Vivo Imaging Laser Capture Microdissection 	Email: o	ct cbr@ad.ucsd.edu	5	mail: ccbr@	Dad.ucsd.edu		
Microarray	Servio	e Profile					
Microscopy Nutrition	paraffin	The Biorepository contains plasma, serum, RNA stabilized buffy coat, urine, viable tumor samples, and formalin-fixed paraffin-embedded tumor — all with associated clinical information. These can be provided to investigators with Cancer					
Radiation Medicine		Sample Banking Committee approval. (IRB approval is also required for projects requesting ongoing sample collection or clinical annotation.) Urine and blood-derived specimens are available from a wide variety of cancer cases and cancer-					
Transgenic Core and Embryonic Stem Cell Free controls. Tumor sample availability is more limited. Samples are collected from consented subjects, and de- identified clinical information on the subjects is available. Subjects are consented for research germ line genotyping. Access to the clinical annotation is determined based on need as justified in each investigator's request or protocol. Anonymized samples from the biorepository are available compliant with UC San Diego HRPP exempt category 4. For projects requiring ongoing sample collection or clinical annotation, Human Subjects Research Review is required. For outside users, the biorepository can assist with identifying a UC San Diego clinical investigator to collaborate on this process.							
UC San Diego I	Health System				858-657-7000 📑 💌 in 📇 🖥		

Locations & Direction Appointments Find a Doctor About Us Contact Us pecialties & Programs ancer Types A-Z ancer Care Centers upport Services ealthy Eating Program linical Trials linical Trials Search bout the Clinical Trials ffice

For Health Professiona Refer a Patient Find a Clinical Trial MCC Faculty & Staff Cancer Services Locations Moores Cancer Center Thornton Hospital **BIOSPECIMEN REQUESTS REQUIRE PREPLANNING**

TISSUE BIOSPECIMENS REQUIRE THE MOST TIME




Data Elements of Biospecimen Request in PDF format

- Project Title, <u>Abstract</u> & Specific Aims
- Any MCC or other C3 collaborating investigators
- **Biospecimen Type Requested for <u>each</u> disease site/tumor type
 - 1) tissue-frozen, FFPE, viable
 - 2) blood-serum, plasma, buffy coat
 - 3) urine
 - 4) saliva
 - Amount/Sample, Number of Samples/Cases for <u>each</u> tumor type/disease site

• Funding Source:

- Intramural/Institutional
- NIH Research Grant
- NIH Career Development Award
- NIH Research Training and Fellowship Awards
- NIH Program Project/Center Grants
- CIRM Grant
- CA Discovery Grant
- Industry Sponsored/Clinical Trial Funding



Criteria For Committee Review

- Overall Scientific Merit/Relevance
- Quality of Research Relevant for Current/Future Funding
- Urgent Clinical Trial/Translational Research/Biomarker Development
- Collaborations with Cancer Center Members
- Demand/Rarity of Specific Tissue Types & Biostatistical Relevance
 - coordination/sharing of sample analytes
- Prior Inventory Commitments/Targeted Prospective Specific Acquisitions (Funded R01/P01/P50)
- IRB approval (may be necessary but <u>not</u> sufficient)

Obligations of Biorepository Use

- Acknowledge use of the Moores Cancer Center BTTSR and <u>cite</u> the <u>CCSG Grant P30CA23100</u> in all presentations and publications that describe data derived from the biospecimen or tissue technology resources.
- Report back to the BTTSR all specimen uses histology/morphologic analysis, genomics/epigenomics, gene expression, proteomics, etc. (not specific data) and whether there are residual analytes.
- Do not transfer the biospecimen or its analytes to third parties.